Acing the future of covalent medicines
Joined January 2022
- Tweets12
- Following1
- Followers136
- Likes0
We’re happy to announce John O’Malley, M.D., Ph.D., as CMO. John’s deep immunology expertise spans academic research, clinical practice, and leadership roles at CRISPR Therapeutics, Sanofi, and Brigham and Women’s Hospital. Welcome to the team, John!
bit.ly/4s3R6D6
Today we announced the successful closing of a $150 million Series B financing. The proceeds from the financing will support progression of the lead asset, MPT-062, to clinical proof-of-concept and advancement of our broader product pipeline.
Co-led by Nextech Invest and Norwest, the financing also included new investors Invus, BB Biotech, T1D Fund, & BOLD Longevity Growth, as well as Access Biotechnology, Atlas Venture, Sanofi Ventures, Digitalis Ventures, and all other existing investors. bit.ly/4drpRN3
We’re thrilled to be working with @Novartis to develop oral covalent inhibitors directed at a transcription factor, and historically hard-to-drug protein, linked to a number of inflammatory diseases. bit.ly/40vzkfJ
Matchpoint brings together passionate drug hunters, technical experts, and seasoned company builders - unified by our values and the goal of developing precision covalent medicines that transform the lives of those impacted by serious disease. matchpointtx.com
Edward Chouchani comments on how our ACE platform can overcome the challenges that previously limited the development of precision covalent medicines. bit.ly/3S2nFOf
The resurgence of covalent medicines ~15 years ago led to important medicines. With our Series A, we are building on this legacy by deploying the power of covalency to the field of immunology. Chairman of our BOD, Bruce Booth, comments. bit.ly/3S2nFOf @LifeSciVC
Our Co-founder Nathanael Gray shares his thoughts on where our platform can go, and how it has the potential to screen for highly selective medicines early in the discovery process. bit.ly/3S2nFOf
At Matchpoint we’re exclusively developing covalent medicines and have set our sights on transforming the treatment of serious immune diseases. bit.ly/3S2nFOf
Today we announced the launch of Matchpoint Therapeutics - founded to harness the power of covalency to develop precision small molecule medicines for immune diseases. Check out the press release here. bit.ly/3S2nFOf
